drugset
drugset / Trial / NCT02514603

A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers

NCT02514603 ↗

Phase 1 Completed 12 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to assess the tolerability of prexasertib in Japanese participants with advanced solid cancers.

Timeline

Start
2015-10
Primary completion
2017-04-10
Completion
2017-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Prexasertib Small molecule — Intravenous

Indications

neoplasm